Advertisement

Real-life-Studie zu psoriasiformen Nebenwirkungen unter TNF-α-Antagonisten bei entzündlichen Darmerkrankungen

  • Hans-Hartmut Peter
Klinische Studien kurzgefasst
  • 3 Downloads

Originalpublikation

Bae JM et al (2018) Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther 2018 Jul;48(2):196–205.  https://doi.org/10.1111/apt.14822. Epub 2018 Jun 5. PubMed PMID:29869804.

According to a recent publication by South Korean researchers patients with inflammatory bowel disease (IBD) who were treated for at least 6 months with tumor necrosis factor antagonists (anti-TNF alpha) are at a highly significant risk for developing psoriasis, palmoplantar pustulosis and psoriatic arthritis.

The authors conducted a nationwide population-based cohort study utilizing National Health Insurance claims data to retrospectively identify patients with IBD (over 50,500 patients) who were treated with anti-TNF alpha agents for >6 months (almost 5500 patients). These patients were compared with control patients who had never taken anti-TNF alpha...

Real-life study of psoriasiform side effects from tumor necrosis factor antagonists in inflammatory bowel diseases

Notes

Interessenkonflikt

H.-H. Peter gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Bae JM, Lee HH, Lee BI, Lee KM, Eun SH, Cho ML, Kim JS, Park JM, Cho YS, Lee IS, Kim SW, Choi H, Choi MG (2018) Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther 48(2):196–205.  https://doi.org/10.1111/apt.14822 CrossRefPubMedGoogle Scholar
  2. 2.
    Fouache D, Goeb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M et al (2009) Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxf) 48(7):761–764CrossRefGoogle Scholar
  3. 3.
    Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M et al (2007) Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol 34(2):380–385PubMedGoogle Scholar
  4. 4.
    Collamer AN, Guerrero KT, Henning JS, Battafarano DF (2008) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 59(7):996–1001CrossRefPubMedGoogle Scholar
  5. 5.
    Kip KE, Swoger JM, Grandinetti LM, Barrie AM 3rd, Greer JB, Regueiro MD (2013) Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system. Inflamm Bowel Dis 19(6):1164–1172CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.FreiburgDeutschland

Personalised recommendations